METAMIZOLO RATIOPHARM ® Metamizole

METAMIZOL RATIOPHARM ® is a drug based on sodium noramidopirina methanesulfonate (metamizole)

THERAPEUTIC GROUP: Non-steroidal analgesics, pyrazolones

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications METAMIZOLO RATIOPHARM ® Metamizole

METAMIZOL RATIOPHARM ® is indicated for the symptomatic treatment of acute acute pain on an inflammatory or post-surgical basis.

Mechanism of action METAMIZOL RATIOPHARM ® Metamizole

METAMIZOLO RATIOPHARM ® is one of the many generic drugs available on the market based on metamizole, an active ingredient considered for its multiple biological activities both in the class of analgesics and non-steroidal anti-inflammatory drugs.

In fact, its therapeutic properties, very useful in overcoming painful states both acute and chronic, are carried out through a series of molecular mechanisms that involve the inhibition of cyclooxygenases, enzymes expressed during particular events of harmful nature, and which catalyze the synthesis of chemical mediators with activities:

Pro-inflammatory, facilitating vasodilation, vasopermeability and chemotactic recruitment processes;
Algica, activating the nerve endings of peripheral nociceptors, and lowering the pain threshold to the central level;
Pyrogenic, increasing the normal thermal set to the hypothalamic level;
Injury, facilitating the process of degranulation with consequent transfer of enzymes with lytic activity.

It is therefore easy to imagine how the inhibition of this process translates into a general improvement in the symptoms linked to phlogistic events.

Recent studies have also shown that metamizole can also present a certain spasmolytic activity, thus being effective also in the reduction of colic-visceral pain.

Studies carried out and clinical efficacy

1.THE METAMIZOL PHARMACOCINETICS

Br J Clin Pharmacol. 2012 Apr 23.

Interesting pharmacokinetic work that demonstrates how the intake of metamizole orally, even if only for 4 days, can significantly alter the concentrations of some subsitrates of the enzyme CYP2B6, determining in some cases also important therapeutic variations. These studies highlight the need to carefully evaluate all possible drug interactions.

2. THE DIPIRONE AS NEUROPROTECTOR

Neurosurgery. 2011 Oct; 69 (4): 942-56.

Innovative experimental study that demonstrates how metamizole can exert neuroprotective action against neurons damaged by inflammatory processes, inhibiting cell death following cerebral ischemia

3.METAMIZOLO AND ACUTE RENAL FAILURE

Ren Fail. 2011; 33 (5): 544-7. Epub 2011 Mar 29.

Case-report that reports the appearance of acute renal failure following the maximum ingestion of metamizole. Fortunately cortisone therapy and adequate rehydration therapy was sufficient to guarantee prompt remission

Method of use and dosage

METAMIZOLO RATIOPHARM ®

Oral drops of 500 mg of metamizole per ml of solution;

Treatment with the relative dosages should be established by your doctor, considering the patient's health conditions, the physio-pathological state and the severity of the clinical picture.

Generally in adults, the intake of 10 - 40 drops diluted in a little water, 3-4 times a day, is effective and free of particular side effects.

Warnings METAMIZOLO RATIOPHARM ® Metamizole

In order to minimize the occurrence of side effects, especially against the gastro-enteric mucosa, we recommend taking METAMIZOLO RATIOPHARM ® preferably on a full stomach limiting the treatment to the strict period necessary for overcoming the pain symptoms.

The dosages normally used should be reviewed in patients suffering from cardiovascular, coagulative, renal, hepatic, allergic and gastrointestinal diseases, given the increased susceptibility of these to adverse reactions induced by drug therapy with NSAIDs.

If unwanted adverse reactions occur, the patient should immediately contact their doctor, with whom they can evaluate the possibility of suspending the drug therapy in progress.

PREGNANCY AND BREASTFEEDING

Taking METAMIZOLO RATIOPHARM ® is contraindicated during pregnancy and lactation due to the numerous side effects affecting the fetus, described in the literature.

Cardiovascular and respiratory malformations and unwanted abortions represent the main problems associated with the prolonged intake of metamizole in pregnancy, to which are added the increased risk of bleeding in the parturient and the numerous complications during childbirth, due to the reduction of contractions of the uterine musculature.

Interactions

Given the antipyretic effects of metamizole, the patient should pay particular attention to the simultaneous administration of other active ingredients with the same effect, due to the increased risk of hypothermia.

Moreover it would be appropriate to consider as the contextual assumption of:

Oral anticoagulants and inhibitors of serotonin reuptake, may increase the risk of bleeding;
Diuretics, ACE inhibitors, angiotensin II antagonists, methotrexate and cyclosporin, may enhance the hepatotoxic and nephrotoxic effects of metamizole;
Non-steroidal anti-inflammatory and corticosteroids, can contribute to the onset of damage to the gastro-enteric mucosa;
Antibiotics, may alter the normal pharmacokinetic and pharmacodynamic properties;
Sulfonylureas, can lead to an imbalance of glucose homeostasis with sudden and severe hypoglycemia.

Contraindications METAMIZOL RATIOPHARM ® Metamizole

Taking METAMIZOLO RATIOPHARM ® is contraindicated in case of hypersensitivity to the active ingredient or to one of its excipients, angioedema, peptic ulcer, history of intestinal bleeding, ulcerative colitis, Crohn's disease or previous history for the same diseases, cerebrovascular bleeding, bleeding diathesis or concomitant anticoagulant therapy, renal failure, liver failure, glucose deficiency 6 phosphate dehydrogenase, asthma, hypophosphataemia and viral infections.

Undesirable effects - Side effects

As with most non-steroidal anti-inflammatory drugs, the administration of METAMIZOL RATIOPHARM ® could also be associated with the appearance of side effects from the different clinical course.

Several clinical trials and careful post-marketing monitoring have in fact shown how the use of metamizole, prolonged over time or taken at doses much higher than the norm, can facilitate the appearance of side effects on the:

Gastrointestinal system with gastric pyrosis, gastralgia, nausea and vomiting, constipation and in more severe cases ulcers and hemorrhages;
Hematopoietic apparatus with increased bleeding time accompanied in severe cases by pancytopenia;
Sensory system with loss of hearing and sight, headache, insomnia, drowsiness, confusion and tremors;
Integumentary system with erythema, rash, urticaria and in severe cases bullous reactions;
Cardiovascular system subjected to an increased risk of cerebro and cardiovascular events.